(Q45326017)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Thomas Thomaidis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Martin Sprinzl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Stephan Kanzler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jochen Raedle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Matthias Ebert

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Carl Cristoph Schimanski

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Peter Robert Galle

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Thomas Hoehler

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Markus Moehler

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische Onkologie), Germany

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

27 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

288-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23532629%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10147-013-0544-7

27 February 2020

exact match

0 references

cites work

rHuEPO and treatment outcomes: the clinical experience

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Incidence and mortality from stomach cancer in Japan, Slovenia and the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Evaluation of experiments with adaptive interim analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0544-7

Breast cancer trial with erythropoietin terminated unexpectedly

21 January 2018

1 reference

12 December 2020

Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly

1 reference

12 December 2020

The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma

1 reference

12 December 2020

Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer

1 reference

12 December 2020

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer

1 reference

12 December 2020

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

1 reference

12 December 2020